Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
about
Hepatitis C virus: Promising discoveries and new treatments(4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus EntrySymbiotic chemo- and immuno-therapy for hepatitis B and C virusesTreatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapyConsensus statement on the management of patients with HCV infection in Romania.New Therapies for Hepatitis C Virus Infection.Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacistEfficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.Emerging biological agents for hepatitis C.Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015).Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates.Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease.Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration.Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer.The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry.Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.A plant-derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry.Addressing the selectivity and toxicity of antiviral nucleosides.Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies.Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village.Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis.Can hepatitis C virus be eliminated by 2030? Saudi Arabia as an example
P2860
Q27468916-A558331A-F6F0-4DD9-BC1A-024C6ACF7DACQ27468939-9DD84FAB-F8C0-46E5-8628-19DF99AE7777Q27468956-C4934239-02AE-4C24-9FB7-C05CAB02ADACQ28073100-863F914B-15E8-4A75-8F19-72820AFC2F8AQ30360535-65EB9A4C-722E-4101-B79A-48CBCFF2AE2CQ33560181-44A48F13-681E-46E9-B920-4294EF6DF4E3Q37630878-5A210DE6-D13D-4C7B-A8A9-B72541B806BCQ38384095-710CC0CC-2394-48C8-9E70-A7FE30B3DBAFQ38798716-F0E2F6BA-FC58-4D4E-9D6B-2B7D8B31DBC5Q38820156-9FBB800A-8BF2-424B-B8D9-D0A315727BFCQ39038238-7527C009-A8F3-470A-B32E-1A697E5AADFDQ39146320-E2E2BD06-ED3D-4B17-BC4C-5D0F6ECAB48DQ40053677-65742634-C4CE-49C1-B08E-85E7FEEFD073Q40060636-D8023B0A-A710-4F66-B201-953A21F17C1BQ40215846-FA4D9E1E-1DEF-4AC3-BF50-B3DB3D016720Q40263873-BF90AC1E-D2C1-4DCE-97A5-04BE9BD345F2Q40320642-2A85721E-7825-4618-8938-6B22EDA6F80CQ40323892-499BB64E-F195-469A-83CC-3E35E53FFF0BQ40333554-E22EB246-A12A-4797-9A1A-3B18F7152B5FQ40353248-A486A520-112D-448D-B812-441EB277033CQ40431770-426DC539-B759-46D9-B931-0F1C24F44F80Q40487793-2332ADEF-5D85-42B9-9E7A-2A4413C51AFDQ40567336-DDD02D9C-D05C-468D-A7F2-E7BC2F668D21Q40711136-65B349EC-87BF-4167-ACB8-68E8709DDCC2Q41934673-BFD9893F-C754-446F-828B-B95FF3EA585EQ41981846-E91CDCFA-F5A7-4BDF-B453-1F988373449FQ52657691-C9675289-2E81-445E-B206-7FF41D359D8FQ54234625-2A8BB1E0-0C6B-4E03-865C-1CE0848A6255Q54964642-E2FFD8BD-3CA2-4347-BDFE-18184CCE036EQ55050518-0268710E-B08B-4850-B727-4BC0FA62C6D6Q55069588-AA3E84C7-4BD3-4326-BC74-247CE9C5F18CQ58804001-0AB0A78C-1EF7-4DB3-8C22-2679E8BCEFD8
P2860
Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Review article: safety and tol ...... ew era of hepatitis C therapy.
@en
type
label
Review article: safety and tol ...... ew era of hepatitis C therapy.
@en
prefLabel
Review article: safety and tol ...... ew era of hepatitis C therapy.
@en
P2860
P356
P1476
Review article: safety and tol ...... ew era of hepatitis C therapy.
@en
P2093
P2860
P304
P356
10.1111/APT.13514
P407
P577
2016-01-20T00:00:00Z